Literature DB >> 21664779

MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy.

Kazuna Takeda1, Shotaro Kanao, Tomohisa Okada, Takayuki Ueno, Masakazu Toi, Hiroshi Ishiguro, Yoshiki Mikami, Shiro Tanaka, Kaori Togashi.   

Abstract

AIM: To investigate if there is any difference in evaluation of residual tumor size after neoadjuvant chemotherapy (NAC) and neoadjuvant endocrine therapy (NAE).
METHODS: Seventy-eight tumors in 57 patients were prospectively enrolled. Residual tumor sizes in contrast-enhanced MRI after NAC and NAE were compared with those measured on surgical specimen by using linear regression analyses. The line slope values >1 indicates overestimation by MRI. Differences in types of shrinkage patterns: concentric shrinkage (CS) and dendritic shrinkage (DS) were also investigated.
RESULTS: Fifty lesions were treated with NAC and 28 lesions were treated with NAE. Shrinkage patterns were CS in 33 lesions and in 45 lesions. The slopes values were 0.75 (R=0.92) and 0.70 (R=0.90) for NAC and NAE, respectively, and no significant difference was observed (p=0.46). However, they were 1.02 (R=0.92) and 0.68 (R=0.92), respectively for CS and DS with significant difference (p<0.01). The difference between CS and DS was found only in a subgroup with size by MRI >20 mm.
CONCLUSION: Contrast enhanced MRI enabled fairly accurate measurement in NAE as well as in NAC.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21664779     DOI: 10.1016/j.ejrad.2011.05.013

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  2 in total

1.  Kinetic information from dynamic contrast-enhanced MRI enables prediction of residual cancer burden and prognosis in triple-negative breast cancer: a retrospective study.

Authors:  Ayane Yamaguchi; Maya Honda; Hiroshi Ishiguro; Masako Kataoka; Tatsuki R Kataoka; Hanako Shimizu; Masae Torii; Yukiko Mori; Nobuko Kawaguchi-Sakita; Kentaro Ueno; Masahiro Kawashima; Masahiro Takada; Eiji Suzuki; Yuji Nakamoto; Kosuke Kawaguchi; Masakazu Toi
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

2.  The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study.

Authors:  Covadonga Martí; Laura Yébenes; José María Oliver; Elisa Moreno; Laura Frías; Alberto Berjón; Adolfo Loayza; Marcos Meléndez; María José Roca; Vicenta Córdoba; David Hardisson; María Ángeles Rodríguez; José Ignacio Sánchez-Méndez
Journal:  Curr Oncol       Date:  2022-03-23       Impact factor: 3.109

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.